Compare SR & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SR | IRTC |
|---|---|---|
| Founded | 1857 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.8B |
| IPO Year | N/A | 2016 |
| Metric | SR | IRTC |
|---|---|---|
| Price | $82.47 | $178.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $85.91 | ★ $203.93 |
| AVG Volume (30 Days) | 432.9K | ★ 502.0K |
| Earning Date | 11-14-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | ★ 4.30 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,476,400,000.00 | $702,573,000.00 |
| Revenue This Year | $13.96 | $27.20 |
| Revenue Next Year | $9.43 | $16.89 |
| P/E Ratio | $18.86 | ★ N/A |
| Revenue Growth | N/A | ★ 25.45 |
| 52 Week Low | $64.44 | $81.10 |
| 52 Week High | $91.11 | $212.00 |
| Indicator | SR | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 48.16 |
| Support Level | $84.78 | $155.00 |
| Resistance Level | $88.66 | $187.98 |
| Average True Range (ATR) | 1.83 | 7.57 |
| MACD | -0.70 | 0.24 |
| Stochastic Oscillator | 4.59 | 60.74 |
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.